Elan is at risk of losing US$2 billion market value once Royalty Pharma walks away with its takeover deal.
Tags: Royalty Pharma
Perrigo awaits decision for Elan Corp acquisition
Perrigo Co is now in a waiting game as it waits for the decision regarding the acquisition of Elan Corp.
Royalty to Explore Ways to Bid for Elan with Partner
Royalty Pharma held internal discussions about making a new bid for Elan Corp according to four sources.
Elan Shareholders Favor Share Buyback
On Monday, Elan shareholders approved a share buyback and put itself up for sale on Friday. (Photo : Reuters)The image is the logo of Elan Pharmaceuticals.
CEOs Fight for Elan, the Biggest Hostile Bid of the Year
Since February, top executives of Elan and Royalty Pharma have been vying to control over Elan. (Photo : Reuters )Irish drugmaker Elan will be giving back $1 billion to shareholders as a boost from the sale of its stake in multiple sclerosis treatment Tysabri to partner Biogen Idec.
Latest News
The following bids, mergers, acquisitions and disposals were reported on Tuesday The following bids, mergers, acquisitions and disposals were reported on Tuesday:- Google Inc bought Israeli mapping startup Waze on Tuesday for just over $1 billion, a source familiar with the matter said, acquiring an online real-time mapping service to safeguard its lead in one of the most crucial aspects of smartphone usage.
Elan rejects the newest bid from Royalty and seeks to look at other unsolicited interested parties.
Royalty Pharma urged the federal court in New York to lift the temporary restraining order it has ordered for the Royalty-Elan bid.
Royalty Pharma raised its hostile bid for Irish drug firm, Elan from US$12.50 to US$13. (Photo : Reuters)The image is the corporate logo of Royalty Pharma, the healthcare focused equity fund.
Royalty Pharma extends deadline for Elan to respond to its unsolicited offer. The private equity firm that invests in royalty streams from pharmaceuticals, Royalty Pharma, had extended the deadline for Elan Corp to respond to its US$6.
Two separate courts issued temporary restraining orders, restricting Royalty Pharma to bid for Elan.
Royalty Pharma increases offer for Elan. Royalty Pharma has increased its offer to purchase Elan Corp by 12%. The new bid is now worth US$6. 4 billion, even after the Irish drugmaker has been making moves seeking to prevent the takeover bid and boost revenues for the company.
Elan purchases two new interests as well as plan for another buyback option to blunt the Royalty Pharma drug offer.
Elan Corp pulls off deal for Theravance respiratory medication royalties from GlaxoSmithKline. Elan Corporation, the Irish pharmaceutical firm has entered into an agreement on royalties to alleviate concerns about its acquisition strategy as well as be able to blunt the takeover bid of Royalty Pharma.
